Insect cells as HLA-restricted antigen-presenting cells for the IFN-γ Elispot assay

Journal of Immunological Methods

Volumn 234, Issue 1-2, 2000, Pages 1-12

  Janetzki, Sylvia ^a   Song, Ping ^a   Gupta, Vanita ^a   Lewis, Jonathan J ^a   Houghton, Alan N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antigen presenting cells; IFN Elispot; Immunotherapy; Insect cells

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; ASSAY; CELL CULTURE; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXICITY; DROSOPHILA MELANOGASTER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INSECT; LEPIDOPTERA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL CULTURE TECHNIQUES; CELL LINE; DROSOPHILA MELANOGASTER; ENZYME-LINKED IMMUNOSORBENT ASSAY; HLA-A2 ANTIGEN; HUMANS; INFLUENZA A VIRUS; INTERFERON TYPE II; PEPTIDES; SPODOPTERA; TIME FACTORS; TRANSFECTION; VIRAL MATRIX PROTEINS;

ANIMALIA; DROSOPHILA MELANOGASTER; INSECTA; LEPIDOPTERA; MELANOGASTER;

EID: 0033973916     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00203-3     Document Type: Article

References (46)

1. Altmann J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94.
2. Boyd A.W., Wawryk S.O., Burns G.E., Fecondo J.V. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc. Natl. Acad. Sci. U. S. A. 85:1988;3095.
3. + T cells during an acute viral infection. Immunity. 8:1998;167.
4. Cormier J.N., Salgaller M.L., Prevette T., Baracchini K.C., Rivoltini L., Restifo N.P., Rosenberg S.A., Marincola F.M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:1997;37.
5. Coulie P. Human tumor antigens recognized by T cells: new perspectives for anti-cancer vaccines. Mol. Med. Today. 3:1997;261.
6. Czerkinsky C., Andersson G., Ekre H.-P., Nilsson L.-Å., Klareskog L., Ouchterlony Ö. Reverse elispot assay for clonal analysis of cytokine production: I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods. 110:1988;29.
7. Duchler M., Offterdinger M., Holzmuller H., Lipp J., Chu C.T., Aschauer B., Bach F.H., Hofer E. NKG2-C is a receptor on human natural killer cells that recognizes structures on K562 target cells. Eur. J. Immunol. 25:1995;2923.
8. ElGhazali G.E.B., Paulie S., Andersson G., Hansson Y., Holmquist G., Olsson T., Ekre H.-P., Troye-Blomberg M. Number of interleukin-4- and interferon-γ-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phythemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur. J. Immunol. 23:1993;2740.
9. Ennis P.D., Zemmour J., Salter R.D., Parham P. Rapid cloning of HLA-A, B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc. Natl. Acad. Sci. U. S. A. 87:1990;2833.
10. Henderson R.A., Michel H., Sakaguchi K., Shabanowitz J., Apella E., Hunt D.F., Engelhard V.H. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 255:1992;1264.
11. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods. 191:1996;131.
12. + T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J. Immunol. Methods. 203:1997;141.
13. Holcombe H.R., Castano A.R., Cheroutre H., Teitell M., Maher J.K., Peterson P.A., Kronenberg M. Nonclassical behavior of the thymus leukemia antigen: peptide transporter-independent expression of a non-classical class I molecule. J. Exp. Med. 181:1995;1433.
14. Hosken N.A., Bevan M.J. Defective presentation of endogenous antigen by a cell line expressing calls I molecules. Science. 248:1990;367.
15. Houbiers J.G., Nijman H.W., Van der Burg S.H., Drijfhout J.W., Kenemans P., Van de Velde C.J., Brand A., Momburg F., Kast W.M., Melief C.J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:1993;2072.
16. Howell D.M., Feldman S.B., Kloser P., Fitzgerald-Bocarsly P. Decreased frequency of functional natural interferon-producing cells in peripheral blood of patients with the acquired immune deficiency syndrome. Clin. Immunol. Immunopathol. 71:1994;223.
17. Jackson M.R., Song E.S., Yang Y., Peterson P.A. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc. Natl. Acad. Sci. U. S. A. 89:1992;12117.
18. Jackson M.R., Cohen-Doyle M.F., Peterson P.A., Williams D.B. Regulation of MHC class I transport by the molecular chaperone, Calnexin (p88, IP90). Science. 263:1994;384.
19. Jäger E., Bernhard H., Romero P., Ringhoffer M., Arand M., Karbach J., Ilsemann C., Hagedorn M., Knuth A. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer. 66:1996;162.
20. Janetzki S., Palla D., Rosenhauer V., Lochs H., Srivastava P.K. Immunization of cancer patients with autologous cancer-derived heat-shock protein gp96 preparations: a pilot study. Cell Stress Chaperones. 3:1998;17.
21. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., Apella E., Rosenberg S.A. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:1994;347.
22. Kawakami Y., Eliyahu S., Jennings C., Sakaguchi K., Kang X., Southwood S., Robbins P.F., Sette A., Apella E., Rosenberg S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating lymphocytes associated with in vivo tumor regression. J. Immunol. 154:1995;3461.
23. + memory T cells. J. Exp. Med. 186:1997;859.
24. Lewis J.J., Janetzki S., Wang S., Williams L., Myers M., Livingston P., Chapman P., Houghton A.N. Phase I trial of vaccination with tyrosinase peptide plus QS-21 in melanoma. Am. Soc. Clin. Oncol. 17:1998;428a.
25. Link H., Olsson O., Sun J., Wang W.-Z., Andersson G., Ekre H.-P., Brenner T., Abramsky O., Olsson T. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J. Clin. Invest. 87:1991;2191.
26. Linsley P.S., Brady W., Grosmaire L., Aruffo A., Damle N.K., Ledbetter J.A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:1991;721.
27. Lucki, A.M., 1986. Transplantation, the limits of recognition. In: Gupter, A.P. (Ed.), Haemocytic and Humoral Immunity in Arthropods. Wiley, London, p. 191.
28. Mahanty S., Abrams J.S., King C.L., Limaye A.P., Nutman T.B. Parallel regulation of IL-4 and IL-5 in human helminth infections. J. Immunol. 148:1992;3567.
29. Marchand M., Weynants P., Rankin E., Arienti F., Belli F., Parmiani G., Cascinelli N., Bourlond A., Vanwijck R., Humblet Y. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer. 63:1999;883.
30. Merville P., Pouteil-Noble C., Wijdenes J., Potaux L., Touraine J.L., Banchereau J. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4. Transplantation. 55:1993;639.
31. Mincheff M.S., Meryman H.T. Costimulatory signals necessary for the induction of T cell proliferation. Transplantation. 49:1990;768.
32. Olsson T., Zhi W.W., Höjeberg B., Kostulas V., Yu-Ping J., Anderson G., Ekre H.-P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ J. Clin. Invest. 86:1990;981.
33. Rio D.C., Rubin G.M. Transformation of cultured Drosophila melanogaster cells with a dominant selectable marker. Mol. Cell. Biol. 5:1985;1833.
34. Romero P., Cerottini J.-C., Waanders G.A. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol. Med. Today. 4:1998;305.
35. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321.
36. Salcedo M., Momburg F., Hämmerling G.J., Ljunggren H.-G. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells. J. Immunol. 152:1994;1702.
37. Salter R.D., Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant T×B cell hybrid. EMBO J. 5:1986;943.
38. + T lymphocytes specific for HLA-class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res. 3:1997;221.
39. Schwartz R.H. A cell culture model for T lymphocyte clonal anergy. Science. 248:1990;1349.
40. Steinle A., Schendel D.J. HLA class I alleles of LCL721 and 174×CEM.T2 (T2). Tissue Antigens. 44:1994;268.
41. + T cells: implications for tumor immunotherapy. Immunity. 4:1996;555.
42. Wei M.L., Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 356:1992;443.
43. Wölfel T., Van Pel A., Brichard V., Schneider J., Seliger B., Meyer zum Büschenfelde K.-H., Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:1994;759.
44. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281.
45. Zemmour J., Little A.-M., Schendel D.J., Parham P. The HLA-A, B "negative" mutant cell line C1R expresses a novel HLA-B25 allele which also has a point mutation on the translation initiation codon. J. Immunol. 148:1992;1941.
46. Zweerink H.J., Gammon M.C., Utz U., Sauma S.Y., Harrer T., Hawkins J.C., Johnson R.P., Sirotina A., Hermes J.D., Walker B.D., Biddison W.E. Presentation of endogenous peptides to MHC classI-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 150:1993;1763.